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Abstract: Previous research has shown that propolis has immunomodulatory activity. Extracts from
two UK propolis samples were assessed for their anti-inflammatory activities by investigating their
ability to alter the production of the cytokines: tumour necrosis factor-α (TNF-α), interleukin-1β
(IL-1β), IL-6, and IL-10 from mouse bone marrow-derived macrophages co-stimulated with
lipopolysaccharide (LPS). The propolis extracts suppressed the secretion of IL-1β and IL-6 with less
effect on TNFα. In addition, propolis reduced the levels of nitric oxide formed by LPS-stimulated
macrophages. Metabolomic profiling was carried out by liquid chromatography (LC) coupled with
mass spectrometry (MS) on a ZIC-pHILIC column. LPS increased the levels of intermediates involved
in nitric oxide biosynthesis; propolis lowered many of these. In addition, LPS produced an increase in
itaconate and citrate, and propolis treatment increased itaconate still further while greatly reducing
citrate levels. Moreover, LPS treatment increased levels of glutathione (GSH) and intermediates in its
biosynthesis, while propolis treatment boosted these still further. In addition, propolis treatment
greatly increased levels of uridine diphosphate (UDP)–sugar conjugates. Overall, the results showed
that propolis extracts exert an anti-inflammatory effect by the inhibition of pro-inflammatory cytokines
and by the metabolic reprogramming of LPS activity in macrophages.
Keywords: propolis; pro- and anti-inflammatory cytokines; LPS stimulation; bone marrow derived
macrophages; metabolomics
1. Introduction
Propolis is collected by bees from plants surrounding the beehive and mixed with bee saliva
and with bees wax. It is used to cover surfaces within the hive prior to laying down the honey comb
and to plug gaps within the hive in order to exclude the outside world. In the UK, Northern Europe,
and North America, propolis is collected from poplar trees and their relatives; in Southern Europe
and North Africa, much of it comes from Cypress trees; and in tropical regions such as Brazil and
West Africa, propolis is usually collected from many different plant sources [1,2]. There are numerous
literature reports on the immunomodulatory effects of propolis [3–8]. In a recent paper, we studied
several types of propolis for their effects on the metabolic response of THP-1 cells to treatment with
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lipopolysaccharide (LPS), and for one sample from Cameroon, which inhibited cytokine release, we
studied the metabolomics of the immune response and found a clear effect of the propolis in inhibiting
purine nucleotide phosphorylase [8]. In addition, there have been some quite extensive trials of
propolis in humans aimed at affecting the immune response [9–13]. The commonly available propolis
supplements, such as glycerol-based tinctures, lozenges, and capsules, are mainly based on temperate
propolis such as that collected by bees in the UK. Thus, in this paper, we study the effects of two
propolis samples collected in the UK on the metabolic response of primary mouse macrophages
challenged with LPS.
There have been several comprehensive studies of the metabolomics response of primary
macrophages to LPS. The major effects of LPS on the metabolome of macrophages can be summarised
as follows: there is a large surge in glycolytic flux with increases in glycolytic intermediates within
the cells, an accumulation of intermediates in the tricarboxylic acid (TCA) cycle, and a rise in the
intermediates in the pentose phosphate pathway (PPP) [14–20]. Macrophages display two main
phenotypes, M1 and M2. The M1 type is induced by LPS treatment [14–20] and is responsible for
the destruction of pathogens, whereas M2 macrophages are responsible for longer-term resistance
to parasites and wound repair [15]. The two phenotypes have different metabolic phenotypes.
M1 produces nitric oxide (NO), which acts as a messenger to promote phagocytosis and also acts
directly in destroying microbes via the formation of peroxynitrite through the reaction between NO
and superoxide. NO production requires increased levels of NADPH, which is required to convert
hydroxy arginine to citrulline and NO [21]. NO formation is an important component in macrophage
activation. The demand for NADPH is high, since the respiratory burst triggered by stimulation
of the macrophages with a pathogen product such as LPS promotes superoxide production, which
also consumes large quantities of NADPH. Nevertheless, the respiratory burst is transient and may
be turned off by antioxidant enzymes within the cell such as superoxide dismutase [22]. However,
this enzyme has GSH as a co-factor, and this results in formation of GSSG, which also requires NADPH
to recycle it back to GSH. The main source of NADPH within the cell is the oxidative arm of the
pentose phosphate pathway, which converts glucose 6-phosphate into 6-phosphogluconate, producing
NADPH in the process. There are other sources of NADPH, but they are more minor and result from
the action of isocitrate lyase [16]. It has been proposed that the accumulation of citrate in macrophages
following stimulation with LPS is an indication of the diversion of this metabolite into NADPH
production [17]. A major recent topic of research has been the alteration of central metabolism when
M1 type macrophages are stimulated with LPS. The macrophages accumulate citrate and succinate,
since the TCA cycle becomes disrupted after succinate, and there is a switch in metabolism towards
glycolysis for ATP generation away from the TCA cycle [17,19,20]. In addition, some of the flux through
the TCA cycle is diverted into the antimicrobial metabolite itaconic acid [23]. The M2 phenotype
does not produce NO, since arginine is metabolised via arginase to produce ornithine rather than
citrulline [17,19,20]. In M2 macrophages, there is shift towards the production of the sugar conjugates
required for the formation of glycan chains on proteins such as UDP-N-acetyl glucosamine, which is
involved in the formation of the pattern recognition receptor CD206, which is strongly expressed in
M2-type macrophages [19,20]. M2 macrophages do not switch their metabolism towards glycolysis
and remain committed to oxidative phosphorylation and show greater levels of fatty acid metabolism
in comparison to M1 macrophages [17,19,20].
Temperate propolis is composed of several hundred components but with around 20 major
constituents, which are flavonoids, flavonoid esters, and phenylpropanoid compounds [24]. Flavonoids
have been shown to inhibit nitric oxide synthase in macrophages and to bind to the PPAR-γ receptor [25].
Thus, it might be expected at the outset that propolis treatment would affect NO biosynthesis and fatty
acid metabolism. The aim of the current study was to study the effect of two samples of temperate
propolis on the metabolomic changes induced in primary macrophages by treatment with LPS.
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2. Results
2.1. The Effect of Propolis on NO Production and Cytokine Production by Macrophages
Figure 1 shows the effect of LPS on NO production in LPS-activated macrophages and the effect
of two different types of propolis from the UK (from Essex and from the Midlands) in inhibiting NO
production. Similarly, treatment with LPS elevated the levels of interleukin-1β (IL-1β), tumour necrosis
factor-α (TFN-α), and IL-6 in macrophages (Figures 2–4), whereas the propolis samples clearly lowered
IL-1β and IL-6 but with less clear effects in lowering TFN-α. Propolis treatment lowers the production
of IL-10, which is considered to be an anti-inflammatory cytokine (Figure 5). This might imply that the
propolis does have some pro-inflammatory effects. Propolis is regarded as being immunomodulatory,
and it is conceivable that it might both regulate and enhance the immune response. The regulation of
IL-10 levels in immune cells is complex [26] and is regulated by other cytokines such as interferons,
which might also be regulated by the propolis.
Figure 1. Effect of two samples of propolis (50 µg/mL) from the UK on nitric oxide (NO) production by
macrophages stimulated by lipopolysaccharide (LPS); n = 6 *** = p value < 0.001. Comparisons of LPS
against medium and LPS + propolis samples 224 and 225 against LPS. Medium alone = M.
Figure 2. Effect of UK propolis (50 µg/mL) on interleukin-1β (IL-1β) production by LPS-stimulated
macrophages; n = 3 * p value < 0.05, ** p value < 0.01, and *** p value < 0.001. Comparisons of LPS
against medium and LPS + propolis samples 224 and 225 against LPS. Medium alone = M.
Figure 3. The effect of UK propolis on IL-6 production in LPS-stimulated macrophages; n = 3 ** p value
< 0.01, *** p value < 0.001. Comparisons of LPS against medium and LPS + propolis samples 224 and
225 against LPS. Medium alone = M.
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Figure 4. The effect of UK propolis on tumour necrosis factor-α (TNF-α) production in LPS-stimulated
macrophages; n = 3 *** p value < 0.001. Comparisons of LPS against medium and LPS + propolis
samples 224 and 225 against LPS.
Figure 5. The effect of UK propolis on IL-10 production in LPS-stimulated macrophages; n = 3 ** p value
< 0.01 *** p value < 0.001. Comparisons of LPS against medium and LPS + propolis samples 224 and
225 against LPS.
2.2. Propolis Does Not Affect Cell Viability
The propolis samples did not affect cell viability of the macrophages at the concentration used
(Figure 6).
Figure 6. The effect of UK propolis on the viability of LPS-stimulated macrophages measured by using
an Alamar blue assay [8].
2.3. The Effect of Propolis on the Metabolomic Profile of Macrophages
Table 1 lists the numerous significant effects on cellular metabolites of the two propolis samples
on the response of the macrophages to LPS treatment.
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Table 1. Metabolites in LPS-stimulated macrophages that are significantly affected by propolis. §—significantly different between all six treatments (LPS-M, LPS-224,
LPS 225, 224-M, 225-M, and 224–225); ¥—Propolis treatments significantly different from controls but not each other; €—Propolis treatments different from LPS but not
the control; #—No difference between 224 and LPS but LPS and 225 differ and treatments differ from control. The false discovery rate statistic (FDR) indicates all
p values < 0.05 are significant. * Matches retention time of standard. p = p value (n = 6 for each treatment). P LM = p value LPS vs. medium treatment; P224L = p value
for propolis sample 224 + LPS vs. LPS; P225L= p value propolis sample 225 + LPS vs. LPS. L/M = LPS treated over medium-treated control, 224/L = propolis sample
224 + LPS over LPS alone, 225/L = propolis sample 225+ LPS over LPS alone.
Anova
Tukey’s HSD m/z Rt min Metabolite P LM L/M P224L 224/L P225L 225/L
Nitric oxide biosynthesis
4.8 × 10−14 ¥ 176.103 16.0 l-Citrulline * 0.001 31.765 0.002 0.199 0.009 0.432
1.8 × 10−18 ¥ 191.114 22.5 N-(Omega)-Hydroxyarginine 0.001 18030.784 0.002 0.056 0.002 0.157
1.0 × 10−14 ¥ 247.140 14.3 N2-(d-1-Carboxyethyl)-l-Arginine 0.002 4.929 <0.001 6.081 <0.001 10.833
3.3 × 10−15 ¥ 291.129 16.8 N-(l-Arginino) Succinate 0.002 24.687 0.002 3.091 0.001 5.223
Glycolysis/TCA cycle
1.9 × 10−8 ¥ 129.018 14.9 Itaconic Acid * 0.000 125.289 0.002 4.069 0.001 5.428
8.0 × 10−8 ¥ 168.990 16.0 Glyceraldehyde 3-Phosphate * 0.003 150.353 0.001 10.092 0.001 12.626
1.3 × 10−7 ¥ 173.021 15.7 Sn-Glycerol 3-Phosphate * 0.002 12.756 0.005 0.289 0.006 0.331
1.4 × 10−6 ¥ 179.0552 14.7 d-Glucose * <0.001 0.429 0.002 0.268 <0.001 0.094
3.0 × 10−16 ¥ 191.0189 18.1 Citrate * <0.001 >1000 <0.001 0.024 <0.001 0.017
3.7 × 10−9 ¥ 666.131 13.3 NADH * 0.009 2.221 0.001 2.477 0.001 3.351
6.1 × 10−7 # 810.131 12.3 Acetyl-CoA 0.004 4.363 0.480 1.213 <0.001 2.257
Oxidative stress/glutathione metabolism
1.3 × 10−13 ¥ 76.040 15.9 Glycine * 0.005 2.367 <0.001 7.222 <0.001 8.452
6.5 × 10−12 ¥ 122.027 14.1 l-Cysteine * 0.027 20.174 0.001 14.423 <0.001 26.437
4.8 × 10−9 ¥ 241.031 16.1 l-Cystine * 0.009 0.492 0.005 0.108 0.005 0.159
6.1 × 10−17 ¥ 251.069 14.1 Gamma-l-Glutamyl-l-Cysteine 0.001 14.204 <0.001 8.063 0.001 14.927
6.4 × 10−11 ¥ 148.060 14.6 l-Glutamate * 0.012 0.729 <0.001 3.126 <0.001 4.074
1.8 × 10−16 ¥ 308.090 14.2 Glutathione * 0.000 3.903 0.001 6.268 <0.001 8.205
1.6 × 10−11 ¥ 336.087 14.6 S-Formylglutathione <0.001 4.273 <0.001 0.536 <0.001 0.518
5.3 × 10−15 ¥ 338.0488 17.3 S-Sulfanylglutathione 0.080 >1000 0.006 326.271 0.005 320.140
1.8 × 10−22 ¥ 380.111 12.1 S-Lactoylglutathione * 0.001 >1000 <0.001 7.408 <0.001 10.455
2.4 × 10−18 ¥ 613.159 17.4 Glutathione Disulphide * 0.001 5.952 <0.001 24.600 <0.001 20.853
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Table 1. Cont.
Anova
Tukey’s HSD m/z Rt min Metabolite P LM L/M P224L 224/L P225L 225/L
High-energy phosphate metabolism
1.1 × 10−10 ¥ 212.043 15.1 Phosphocreatine * 0.001 2.157 0.006 1.768 0.002 2.739
4.5 × 10−10 ¥ 348.070 16.6 AMP * 0.035 4.217 0.007 3.455 0.007 5.228
1.8 × 10−10 ¥ 322.0446 16.0 CMP * 0.002 1.795 0.001 2.107 <0.001 2.095
1.9 × 10−11 ¥ 489.114 15.3 CDP–Choline * 0.001 22.575 0.001 0.142 0.001 0.191
9.6 × 10−13 ¥ 484.975 17.9 UTP * 0.001 0.534 <0.001 7.534 <0.001 11.550
8.2 × 10−11 ¥ 508.002 16.6 ATP * 0.002 1.987 0.001 2.006 0.001 2.416
5.7 × 10−10 ¥ 523.997 19.3 GTP * <0.001 7.584 0.060 1.485 0.002 2.214
4.8 × 10−10 § 565.0477 16.1 UDP–Glucose * 0.897 1.058 0.002 24.657 0.007 50.760
8.4 × 10−10 ¥ 606.0744 15.0 UDP–N-Acetyl-d-glucosamine * 0.107 3.312 0.008 33.266 0.016 46.857
Fatty acid metabolism
3.5 × 10−9 § 185.117 3.9 10-Oxodecanoate 0.318 0.702 <0.001 100.192 0.001 90.767
3.0 × 10−9 ¥ 204.123 11.1 O-Acetylcarnitine * <0.001 4.658 <0.001 0.002 0.490 0.002
1.7 × 10−7 € 218.138 9.9 O-Propanoylcarnitine <0.001 0.321 <0.001 2.871 <0.001 2.967
1.9 × 10−9 § 227.201 4.2 Tetradecanoic Acid <0.001 2.432 0.004 1.413 <0.001 1.464
9.2 × 10−10 § 225.186 4.2 Tetradecenoic Acid 0.126 2.130 0.025 2.131 <0.001 5.490
3.5 × 10−14 § 269.212 4.2 Oxo-Hexadecanoic Acid 0.323 1.305 0.003 38.013 <0.001 257.413
3.4 × 10−10 § 271.228 3.8 Hydroxypalmitate 0.193 0.610 <0.001 129.447 <0.001 132.527
1.7 × 10−9 § 279.231 4.0 Linoleate 0.350 0.340 <0.001 20.934 <0.001 22.371
4.1 × 10−8 § 283.264 3.8 Octadecanoic Acid <0.001 1.779 <0.001 0.589 <0.001 0.537
1.7 × 10−9 § 295.227 3.8 Hydroxyoctadecadienoic Acid 0.293 1.227 0.008 41.194 <0.001 102.576
1.4 × 10−7 § 299.259 3.9 Hydroxyoctadecanoic Acid 0.829 0.937 0.020 29.732 <0.001 68.922
1.7 × 10−6 § 301.217 4.0 Eicosapentaenoic Acid 0.001 1.822 0.001 0.585 0.001 0.583
1.7 × 10−10 § 303.233 4.0 Eicosatetraenoic Acid 0.267 0.938 <0.001 0.511 <0.001 0.509
3.8 × 10−8 § 309.280 3.7 Eicosenoic Acid <0.001 3.417 0.006 0.699 0.001 0.660
1.2 × 10−9 § 327.233 3.7 Docosahexaenoic Acid 0.001 1.905 <0.001 0.336 <0.001 0.395
7.8 × 10−9 § 333.280 3.7 Docosatrienoic Acid <0.001 2.118 <0.001 0.485 <0.001 0.468
2.2 × 10−8 # 386.289 4.9 Hydroxytetradecenoylcarnitine 0.002 9.282 0.107 1.459 <0.001 6.815
7.1 × 10−9 § 414.320 4.9 Hydroxyhexadecenoylcarnitine 0.002 29.177 0.014 2.715 <0.001 4.851
4.0 × 10−10 § 428.373 4.6 Stearoylcarnitine 0.005 1.898 0.001 2.351 0.003 1.699
4.3 × 10−22 § 442.352 7.6 Hydroxyoctadecenoylcarnitine 0.001 >1000 <0.001 13.029 <0.001 11.175
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Table 1. Cont.
Anova
Tukey’s HSD m/z Rt min Metabolite P LM L/M P224L 224/L P225L 225/L
Phospholipid biosynthesis
1.4 × 10−3 € 104.107 14.5 Choline * <0.001 4.826 <0.001 0.407 <0.001 0.379
8.8 × 10−13 ¥ 184.073 15.0 Choline Phosphate * 0.001 2.530 <0.001 2.827 0.001 2.582
2.0 × 10−9 ¥ 258.110 14.5 Sn-Glycero-3-Phosphocholine * <0.001 5.060 0.001 0.427 0.001 0.400
1.9 × 10−11 ¥ 568.339 4.6 LPC 22:6 0.009 2.501 <0.001 3.014 <0.001 2.920
5.0 × 10−8 € 810.526 3.8 PS 38:5 <0.001 3.432 <0.001 0.186 <0.001 0.291
6.0 × 10−5 ¥ 820.619 4.1 PC40:5 0.034 1.269 0.002 0.618 0.001 0.572
Purines and pyrimidines
1.1 × 10−13 § 136.062 9.7 Adenine * <0.001 4.250 <0.001 1.708 <0.001 2.160
1.5 × 10−10 § 137.046 8.3 Hypoxanthine * 0.002 2.386 0.002 4.181 <0.001 6.198
3.4 × 10−8 ¥ 243.062 12.0 Uridine * 0.624 1.141 <0.001 3.804 <0.001 4.458
8.6 × 10−11 § 251.0784 9.6 Deoxyinosine 0.072 2.383 0.007 21.680 <0.001 35.912
5.3 × 10−10 § 284.098 12.7 Guanosine * 0.046 13.235 0.001 23.082 <0.001 29.869
8.3 × 10−09 ¥ 384.114 14.4 Succinyladenosine 0.050 >1000 0.006 3.782 0.006 2.794
Aminosugars
1.5 × 10−7 € 180.086 18.1 d-Glucosamine * <0.001 6.336 <0.001 0.210 <0.001 0.148
1.2 × 10−9 ¥ 222.098 12.7 N-Acetyl-d-Glucosamine * 0.018 21.617 <0.001 5.012 0.003 6.840
4.6 × 10−14 § 266.0895 11.2 Neuraminic Acid 0.164 2.320 <0.001 62.644 <0.001 97.751
8.8 × 10−15 ¥ 300.0489 15.0 N-Acetyl-d-Glucosamine6-Phosphate * 0.003 0.428 <0.001 27.336 <0.001 26.704
3.2 × 10−6 § 310.113 13.2 N-Acetylneuraminate 0.013 2.197 0.002 0.170 0.004 0.297
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2.3.1. Propolis Treatment Inhibits NO Formation
Analysis of the metabolomics data shows the clear effects of LPS in greatly elevating
hydroxyarginine, the intermediate in NO production from arginine, and citrulline, the product
remaining after NO formation. The UK propolis samples have a marked effect on lowering both
hydroxyarginine and citrulline (Figure 7), which fits with the direct measurement indicating lowered
NO formation (Figure 1). The propolis samples also increase arginosuccinate, which is involved in
recycling citrulline back to arginine in order to make more NO, and the accumulation could be due to
the inhibition of conversion of this substrate into arginine. There were no direct effects on arginine
levels, which were the same in the macrophages treated with LPS and LPS + propolis.
Figure 7. Extracted ion traces showing decreases in hydroxy arginine and citrulline in LPS-stimulated
macrophages treated with propolis.
2.3.2. Propolis Treatment May Promote Energy Metabolism and Stimulate the Formation of High
Energy Phosphates
LPS produced moderate increases in NADH and ATP, which are largely derived from the TCA
cycle or fatty acid oxidation, and propolis treatment increased NADH and ATP levels further (Figures 8
and 9). In addition, the levels of other high energy phosphates such as creatine phosphate and uridine
triphosphate (UTP) were increased by propolis treatment (Figures 8 and 9). LPS treatment had a
marked effect on some glycolysis intermediates with a large increase in glyceraldehyde 3-phosphate
(G3P), which was increased still further by the propolis treatments (Table 1).
Figure 8. Extracted ion traces showing increased in phosphocreatine and NADH in LPS-stimulated
macrophages treated with propolis.
Metabolites 2020, 10, 413 9 of 17
Figure 9. Extracted ion traces showing increases in UTP and ATP in LPS-stimulated macrophages
treated with propolis.
2.3.3. Propolis Treatment Stimulates Formation of Amino Sugars
The propolis treatments caused increases in the levels of the amino sugars N-acetyl glucosamine,
neuraminate, and N-acetylglucosamine phosphate (Table 1) as well as increases in UDP–N-acetyl
glucosamine and UDP–glucose (Figure 10). All these intermediates are increased in the LPS-treated
samples and markedly increased in the propolis-treated samples.
Figure 10. Extracted ion trace showing increases in UDP–glucose and UDP–N-acetyl glucosamine in
LPS-stimulated macrophages treated with propolis.
2.3.4. Propolis Treatment Lowers Citrate and Increases Itaconate
Citrate was markedly lowered by propolis treatment in comparison with LPS treatment alone,
and the anti-inflammatory compound itaconic acid was markedly increased by propolis treatment
(Figure 11).
Metabolites 2020, 10, 413 10 of 17
Figure 11. Extracted ion traces showing a decrease in citrate and increase in itaconic acid in
LPS-stimulated macrophages treated with propolis.
2.4. Propolis Treatment Increases GSH Levels
Another important pathway in macrophages is glutathione metabolism, since GSH may modulate
the response of the macrophages and may be responsible for damping down the respiratory burst
following stimulation with a pathogen product [17,19,20]. The propolis treatments increase GSH levels,
and the level of its oxidation product GSSG is also elevated greatly in comparison to LPS treatment
alone (Figure 12). In addition, the propolis treatments elevate all the intermediates involved in GSH
biosynthesis: glycine, cysteine, glutamate, and gammaglutamyl cysteine (Table 1).
Figure 12. Extracted ion traces showing increased in GSH and oxidised glutathione (GSSG) in
LPS-stimulated macrophages treated with propolis.
2.5. Propolis Treatment Increases Fatty Acid Metabolism
One of the major effects of the propolis treatment is on the levels of certain fatty acids, which are
markedly increased, suggesting that this might be due to triglyceride hydrolysis and a switch towards
fatty acid metabolism (Table 1). The increase in fatty acid metabolism is underlined by the elevation of
several acyl carnitines, which are required for the transport of fatty acids into mitochondria so that
β-oxidation can be carried out. A signature of M2 macrophages in comparison with M1 macrophages is
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increased fatty acid metabolism [17,19,20]. Some long-chain fatty acids are increased by LPS treatment
but are markedly lowered by the propolis treatments, including eicosatetraencoic acid, which, as the
precursor of prostaglandins, can be considered pro-inflammatory.
3. Discussion
It is clear from the viability data and the enhancement of energy metabolites such as ATP and
creatine phosphate that propolis if anything increases the viability of the cultured macrophages.
The cytokine assays largely support the reports [3–6] that propolis is anti-inflammatory and the
metabolomics data almost perfectly support the idea that propolis treatment is pushing the macrophages
towards an M2-like character. The conversion of arginine to citrulline with the formation of NO is
inhibited, and levels of GSH and GSSH are increased, pointing towards the promotion of activity
against ROS generation; a number of intermediates required for GSH biosynthesis are elevated by
propolis treatment. UDP-N-acetyl glucosamine, which is used for glycoprotein formation in M2-type
macrophages, is elevated, as are intermediates required for its biosynthesis, UTP, N-acetylglucosamine,
and N-acetylglucosamine phosphate. Of note, UDP-N-acetyl glucosamine is required as a substrate for
the production of glycans on proteins such as the CD206 receptor, which is abundantly expressed in
M2 macrophages. It is well established that in M2 macrophages, some of the glycolytic flux is diverted
into the amino sugar pathway [20]. The propolis-treated macrophages accumulate glyceraldehyde
phosphate to an even greater extent than macrophages treated with LPS alone, suggesting the inhibition
of glyceraldehyde phosphate dehydrogenase; this process can promote methylglyoxal formation from
glyceraldehyde phosphate and dihydroxy acetone phosphate [27]. The elevation of methylglyoxal by
the propolis treatments is supported by a large increase in lactoyl glutathione, which is the cellular
detoxification product of methyl glyoxal [28]. Methyl glyoxal can react with arginine residues in
proteins generating the advanced glycation product carboxyethylarginine, which is elevated following
LPS treatment and further elevated by propolis treatment. Carboxyethyl arginine has been shown to
be an inhibitor of NO production [29]. Citrate accumulates in M1-type macrophages and is important
in sustaining the inflammatory response through supporting fatty acid biosynthesis [17,19,20,30] and
the production of ROS. The propolis treatments hugely deplete citrate. LPS treatment increases the
levels of the anti-inflammatory compound itaconic acid, and propolis treatment increases its levels still
further; there is some evidence that itaconate stimulates M2 macrophage polarisation [23].
The metabolism of eicosatetranenoic acid is carried out by peroxisomes [31], and it has been
shown that PPAR-γ receptor activation can affect macrophage polarisation [32]. Flavonoids have
been shown to inhibit inducible cycloxgenase synthase and nitric oxide synthase by binding to the
PPAR-γ receptor in macrophages [25]. Thus, it would seem that part of the action of propolis may be
due to promoting PPAR-γ receptor activation. This has been found to be a feature of many natural
products [33], including flavonoids that are present in the propolis extracts. It has been observed
that fatty acid metabolism is promoted over glycolysis in M2 macrophages in comparison with M1
macrophages, and the presence of increased levels of several hydroxylated long-chain carnitines and
greatly elevated levels of partially oxidised fatty acids in the propolis-treated samples suggest that the
propolis treatments are promoting the M2 character in the macrophages [34,35].
The two samples used in this study were typical samples of temperate propolis collected from
poplar buds where the composition is well established [24,36]. There are some variations between
samples 224 and 225. The flavanones pinocembrin and pinobanksin (Figures S2 and S4) appear to be
qualitatively similar in the samples, whereas the flavone chrysin and the flavonols galangin methyl
ethers and kaempferol appear to be markedly higher in sample 224 (Figures S1, S3, S5 and S6). It was
previously observed that flavones and flavonols had a greater effect in inhibiting nitric oxide production
by macrophages than flavanones [37–39]. This might explain some of the difference in effect between
224 and 225 on the macrophages.
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4. Materials and Methods
4.1. Chemicals and Reagents
Fetal bovine serum, DMEM (1X), DMEM phenol red free, and RPM-1640 medium were obtained
from Gibco. Glutamine solution, PBS, and penicillin/streptomycin solution were obtained from Lonza.
Six-well cell culture plates were purchased from Thermo Fisher Scientific; 96-well cell culture plates
were purchased from TPP, Switzerland. Ethanol, trypan blue stain, bovine serum albumin, EDTA,
carbonyl cyanide m-chlorophenyl hydrazine, oligomycin A, and ammonium carbonate were obtained
from Sigma-Aldrich, Dorset, UK. HPLC grade methanol, acetonitrile, and water were obtained from
Fisher Scientific, Leicestershire, UK.
4.2. Preparation of Propolis Extracts
The two UK propolis samples were obtained by James Fearnley; sample 224 was from Essex and
sample 225 was from the Midlands. Ethanol extracts of approximately 10 g propolis were prepared by
vigorous mixing and sonication for 60 min using a sonicating bath (Fisher Scientific, Loughborough,
UK). The extracts were filtered and the propolis was re-extracted twice with 100 mL of ethanol (Fisher
Scientific, Loughborough, UK). The extracts were combined and evaporated, and the residue was
stored at room temperature until required for the assays.
4.3. Generation of Bone Marrow-Derived Macrophages (BMMs)
All experiments were approved by and conducted in accordance with the Animal Welfare and
Ethical Review Board of the University of Strathclyde and UK Home Office Regulations. Bone marrow
was collected from the femur and tibia bones of 6–8-week-old male or female BALB/c mice, which
were bred at Strathclyde University and killed by cervical dislocation. Then, bones were dissected
from adherent tissues and washed briefly with 70% ethanol. In sterile conditions, under a tissue
culture hood, the bone ends were cut to allow bone marrow elution through washing the bone DMEM
medium. Then, the eluted bone marrow was collected, filtered using a cell strainer, and centrifuged at
400× g for 5 min. The supernatants were next aspirated and replaced with a known amount of fresh
complete DMEM medium to count the obtained cells, using trypan blue stain in order to culture them
at the required density. Then, cells were plated and cultured on tissue culture Petri dishes at a density
of 2 × 106 cells/mL in complete DMEM with 20% L929 cell supernatant [40] and maintained at 37 ◦C
in a humidified atmosphere of 5% (v/v) CO2. Fresh complete DMEM supplemented with 20% L929
cell supernatant was added on day 4 to feed the macrophages. On day 7, the cells were harvested
by scraping them into 5 mL complete DMEM at 4 ◦C to allow adherent cell detachment, and they
were then collected for further centrifugation at 400× g for 5 min. Then, the viability and number of
cells was checked using trypan blue stain followed by identification by flow cytometry and plating
according to the desired experiments.
4.4. Flow Cytometry
Re-suspended cells with a density of 0.5 × 106/ fluorescence activated cell sorting (FACS) tube
were incubated with anti-mouse CD16/CD32 for 5 min to block subsequent nonspecific binding of
antibodies to Fc receptors. Cells were next incubated with antibodies specific for CD11b-APC (BD
Pharmingen) and F4/80-FITC (eBioscience) along with the Fluorescence Minus One (FMO) controls
(eBioscience and BD Pharmingen) and placed at 4 ◦C for 25 min, after which they were washed in FACS
buffer (2% Bovine Serum Albumin (Sigma-Aldrich, Poole, Dorset, UK) in PBS (Lonza, Slough, UK)
with 2 mM EDTA). Then, the cells were re-suspended in FACS buffer to render them ready for flow
cytometry analysis. Flow cytometry was carried out using a FACS Canto instrument (BD Pharmingen,
San Jose, CA, USA). The purity of differentiated bone marrow-derived macrophages was determined
by the measurement of CD11b and F4/-80 double positive cells. Cultures of >90% were used for
cytokine and metabolomics assays.
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4.5. Effect of Propolis Treatment on LPS-Activated Macrophages
The BMMs were plated at a concentration of 2 × 106 cells/2 mL of complete RPMI medium
(RPMI-1640 (Lonza), 2 mM glutamine (Lonza), 50 U/mL penicillin (Lonza), 50 µg/mL streptomycin
(Lonza), 10% FCS (Gibco, Paisley, UK)) in 6-well plates, with 5 to 6 replicates/each condition used, and
then rested for 5 h or overnight. To study the effect of adding propolis on the macrophage metabolome,
the two sample extracts were added at a concentration of 50 µg/mL along with an equivalent amount
of medium only added to the control group. Then, treated BMMs were incubated for 18 h at 37 ◦C in a
humidified atmosphere of 5% (v/v) CO2. After 18 h of incubation, LPS (Escherichia coli, Sigma Aldrich)
was added to give a concentration of 100 ng/mL, and incubation was continued for a further 24 h.
Cell extracts were prepared by washing the cells once with warm PBS before harvesting the cells
in a chilled extraction solution (MeOH/MeCN/H2O, 50:30:20 v/v) with a concentration of 1 mL of
extraction mix per 2 × 106 cells. Then, cell lysates were collected and shaken at 1200 rpm for 20 min at
4 ◦C before being centrifuged at 0 ◦C at 13,000 rpm for 15 min. Then, the supernatants were collected
and transferred into auto sampler vials for loading into the LC-MS autosampler or storage at −80 ◦C
until analysis.
4.6. Measurement of Cell Viability
The BMM cells were seeded at a density of 2 × 105 cells/well in 96-well plates and incubated for
24 h at 37 ◦C in a humidified atmosphere of 5% CO2. After 4 h of resting, to allow adhesion, the cells
were treated with medium only for the negative control cells and propolis extract (50 µg/mL) and all
incubated for a further 24 h. After 24 h, LPS was added to all cells except the control incubations, for
which incubation was carried out for 24 h. Four hours before the end of the incubation, Alamar blue [8]
was added to all cells, with a slight shaking, and then the plates were returned to the incubator until
the end of treatment. To read the cell viability, 100 µL of all conditions was pipetted into new plates to
measure fluorescence at excitation: 530 nm, emission: 590 nm using a Polarstar Omega plate reader
(BMG Labtech, Aylesbury, UK).
4.7. Measurement of NO Production in BMMs
BMMs were plated and stimulated with propolis pre-treatment followed by LPS activation. First,
50 µL aliquots of cell supernatant were collected and added into wells of a 96-well plate. Then, Griess
reagents (A + B) were mixed in a ratio of 1:1 [2% (w/v) sulphanilamide in 5% (v/v) H3PO4 and 0.2%
(w/v) naphylethylenediamine HCl in water], and 50 µL of the mix were added to the cell supernatants
in each well. Then, the 96-well plate was incubated in the dark for 10 min. Then, the absorbance was
read using a Polarstar Omega plate reader at 540 nm. Nitrite production was determined relative to a
standard curve constructed with solutions of sodium nitrite (NaNO2) as described previously [41]
from a 10 mM stock solution of NaNO2 prepared in complete RPMI 1640 cell medium.
4.8. Cytokine Assays
BMMs were plated and stimulated with propolis pre-treatment followed by LPS activation. First,
50 µL of cell supernatant were collected for analysis using ELISA Ready-Set-Go kits purchased from
Thermo Fisher Scientific (Loughborough, UK).
The assays were performed according to the manufacturer’s instructions to quantify the release
of cytokines: (TNF-α, IL-1β, IL-6, and IL-10). The reaction was stopped using 2 N sulphuric acid.
The plates were read using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA, USA) at
560 nm, and the absorbance values were corrected by subtracting readings. The data obtained were
analysed using Gen5 and Prism 7.
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4.9. Liquid Chromatography/Mass Spectroscopy (LC/MS)
The chromatographic conditions were set as follows: A ZICpHILIC column (150 × 4.6 mm × 5 µm,
Hichrom, Reading, UK) was eluted with a linear gradient over 30 min between 20 mM ammonium
carbonate (pH 9.2)/MeCN (20:80) at 0 min and 20 mM ammonium carbonate (pH 9.2)/MeCN (20:80)
at 30 min with a flow rate of 0.3 mL/min, followed by washing with 20 mM ammonium carbonate
MeCN (95:5) for 5 min and then re-equilibration with the starting conditions for 10 min. LC/MS was
carried out by using a Dionex 3000 HPLC pump coupled to an Exactive (Orbitrap) mass spectrometer
from Thermo Fisher Scientific (Bremen, Germany). The spray voltage was 4.5 kV for positive mode
and 4.0 kV for negative mode. The temperature of the ion transfer capillary was 275 ◦C and sheath
and auxiliary gas were 50 and 17 arbitrary units, respectively. The full scan range was 75 to 1200 m/z
for both positive and negative modes. The data were recorded using the Xcalibur 2.1.0 software
package (Thermo Fisher Scientific, Hemel Hempstead, UK). The signals of 83.0604 m/z (2 × ACN + H)
and 91.0037 m/z (2 × formate-H) were selected as lock masses for the positive and negative modes,
respectively, during each analytical run.
4.10. Metabolomic Data Analysis
Raw data from untargeted metabolomic studies were putatively identified and processed using
Mzmine [42] Prior to further analysis, data were filtered in which metabolites of low intensities
(<1000 peak height) and metabolites that did not show any significant fold changes were excluded
in order to simplify the data for interpretation. Accurate masses were searched against an in-house
database, and in addition, retention times for 200 metabolites were matched against standard mixtures
run at the same time as the samples [43]. Otherwise, metabolite matches were based on accurate
masses < 3 ppm and identified to MSI levels 1, where the retention time matched that of a standard or
to level 2 [44]. Details of the metabolite mixtures were described previously [43].
4.11. Statistical Analysis
The extracted data were exported to Excel in order to calculate p values and metabolite ratios.
Further analysis of the extracted data was carried out by using Metaboanalyst 4.0 [45] in order to
determine ANOVA values between the different treatments. A PDF file with mean extracted peak areas
and standard error of the mean (SEM) values is provided in Supplementary Materials Appendix 1.
5. Conclusions
One might ask what benefit immunomodulation might offer to the bees that collect it. Perhaps
some clue to this is from the recent paper indicating that the honey bee microbiome is stabilised by
propolis [46], and this could in part be mediated by modulation of the immune response as well as by
the control of pathogens by the propolis. Propolis contains hundreds of components with flavonoids
and phenylpropanoid compounds being the major components. However, it may act in the form
of a complex with more minor components also playing a role in its overall activity. Generally, the
well-established anti-protozoal activity of propolis [47] may depend on the activity of the whole
mixture, since usually, isolated components are less active or not more active than the extract mixture.
The current paper provides strong support for propolis being effective as an anti-inflammatory complex.
Propolis has been studied as an immunomodulatory agent in a number of sizeable trials, and its safety
in high doses is good [9–13]. There had been no studies examining whether or not the components in
propolis are absorbed. However, recently, we carried out a small-scale trial looking at the absorption
of the flavonoids from propolis from an oral dose, and it was clear that the flavonoid components
within propolis were generally well absorbed [48]. Such variations in effect vs. composition across
different samples could provide the basis for a subsequent study. The effects of propolis on the immune
response are very interesting, and these in vitro results support the in vivo trials [10–13] aimed at
producing immune modulation. There is a particularly strong need for a more comprehensive study
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of the absorption and metabolism of propolis components to support any claims with regard to its
efficacy in providing immune support.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/10/10/413/s1,
Figure S1: Extracted ion traces for chrysin in samples 225 and 224, Figure S2: Extracted ion traces for pinocembrin
in samples 225 and 224, Figure S3: Extracted ion traces for galangin in samples 225 and 224, Figure S4: Extracted
ion traces for pinobanksin in samples 225 and 224, Figure S5: Extracted ion traces for galangin methyl ethers in
samples 225 and 224, Figure S6: Extracted ion traces for kaempferol in samples 225 and 224, Appendix 1: PDF file
including mean peak areas and associated SEM values for the features extracted from the raw data files.
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